# Pierre-RÃ©gis Burgel

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 166 papers | 7,662 citations | 61687 45 h-index | 68831 81 g-index |
| 176 all docs | 176 docs citations | 176 times ranked | 10320 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 155-159. | 0.3 | 6 |
| 2 | Impact of a high emergency lung transplantation programme for cystic fibrosis in France: insight from a comparison with Canada. European Respiratory Journal, 2022, 59, 2100014. | 3.1 | 7 |
| 3 | Cystic Fibrosis in 2021: â€œThe Times They Are A-Changinâ€• Archivos De Bronconeumologia, 2022, 58, 536-538. | 0.4 | 1 |
| 4 | Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge. Journal of Cystic Fibrosis, 2022, 21, 691-706. | 0.3 | 8 |
| 5 | Diversity of approaches in artificial intelligence: an opportunity for discoveries in thoracic imaging. European Respiratory Journal, 2022, , 2200022. | 3.1 | 0 |
| 6 | Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 489-496. | 0.3 | 38 |
| 7 | Major Decrease in Lung Transplantation for Patients with Cystic Fibrosis in France. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 584-586. | 2.5 | 26 |
| 8 | Change in Lung Function after Initiation of Elexacaftorâ€“Tezacaftorâ€“Ivacaftor: Do Not Forget Anatomy!. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1365-1366. | 2.5 | 1 |
| 9 | Tobramycin safety and efficacy review article. Respiratory Medicine, 2022, 195, 106778. | 1.3 | 5 |
| 10 | Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021. Respiratory Medicine and Research, 2022, 81, 100889. | 0.4 | 0 |
| 11 | Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers. Journal of Clinical and Translational Endocrinology, 2022, 28, 100298. | 1.0 | 2 |
| 12 | Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis. Clinical Infectious Diseases, 2022, 75, 2135-2144. | 2.9 | 9 |
| 13 | People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study. ERJ Open Research, 2022, 8, 00686-2021. | 1.1 | 3 |
| 14 | Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome. European Respiratory Review, 2022, 31, 210259. | 3.0 | 10 |
| 15 | CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. Cells, 2022, 11, 1769. | 1.8 | 17 |
| 16 | No patient left behind! Therapeutic options for cystic fibrosis patients living with lung transplantation. Journal of Cystic Fibrosis, 2022, , . | 0.3 | 0 |
| 17 | Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respiratory Medicine, 2022, 200, 106921. | 1.3 | 14 |
| 18 | Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study. Journal of Cystic Fibrosis, 2022, 21, e221-e231. | 0.3 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. Journal of Cystic Fibrosis, 2021, 20, 220-227. | 0.3 | 24 |
| 20 | Effective control ofStaphylococcus aureuslung infection despite tertiary lymphoid structure disorganisation. European Respiratory Journal, 2021, 57, 2000768. | 3.1 | 6 |
| 21 | Mucus Plugs in Medium-sized Airways: A Novel Imaging Biomarker for Phenotyping Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 932-934. | 2.5 | 2 |
| 22 | Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. Journal of Cystic Fibrosis, 2021, 20, 25-30. | 0.3 | 62 |
| 23 | â€œIl faut continuer Ã poser des questionsâ€•patient reported outcome measures in cystic fibrosis: An anthropological perspective. Journal of Cystic Fibrosis, 2021, 20, e108-e113. | 0.3 | 4 |
| 24 | Rapid Improvement after Starting Elexacaftorâ€“Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 64-73. | 2.5 | 139 |
| 25 | Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus. International Journal of COPD, 2021, Volume 16, 321-332. | 0.9 | 18 |
| 26 | Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000653. | 3.1 | 16 |
| 27 | Burden and Characteristics of Severe Chronic Hypoxemia in a Real-World Cohort of Subjects with COPD. International Journal of COPD, 2021, Volume 16, 1275-1284. | 0.9 | 8 |
| 28 | Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. Journal of Cystic Fibrosis, 2021, 20, 566-577. | 0.3 | 34 |
| 29 | COVID-19 vaccine prioritisation for people with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 715-716. | 0.3 | 5 |
| 30 | Reply to Kuek etÂal.: Optimism with Caution: Elexacaftorâ€“Tezacaftorâ€“Ivacaftor in Patients with Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 372-374. | 2.5 | 10 |
| 31 | COVID-19 outcomes in people with cystic fibrosis. Current Opinion in Pulmonary Medicine, 2021, 27, 538-543. | 1.2 | 13 |
| 32 | Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review. International Journal of COPD, 2021, Volume 16, 2363-2373. | 0.9 | 14 |
| 33 | Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries. European Respiratory Journal, 2021, 58, 2101487. | 3.1 | 2 |
| 34 | Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. Respiratory Medicine and Research, 2021, 80, 100829. | 0.4 | 16 |
| 35 | Management of early infection with Pseudomonas aeruginosa in adults with bronchiectasis: A survey of French pulmonologist's practices. Respiratory Medicine and Research, 2021, 80, 100859. | 0.4 | 0 |
| 36 | Topological data analysis reveals genotypeâ€“phenotype relationships in primary ciliary dyskinesia. European Respiratory Journal, 2021, 58, 2002359. | 3.1 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis. European Respiratory Journal, 2021, , 2101344. | 3.1 | 19 |
| 38 | Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?. European Respiratory Journal, 2021, , 2102924. | 3.1 | 0 |
| 39 | The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine,the, 2020, 8, 65-124. | 5.2 | 573 |
| 40 | Real-Life Safety and Effectiveness of Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 188-197. | 2.5 | 95 |
| 41 | Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375. | 0.3 | 24 |
| 42 | Arpin is critical for phagocytosis in macrophages and is targeted by human rhinovirus. EMBO Reports, 2020, 21, e47963. | 2.0 | 17 |
| 43 | Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287. | 3.0 | 82 |
| 44 | First Wave of COVID-19 in French Patients with Cystic Fibrosis. Journal of Clinical Medicine, 2020, 9, 3624. | 1.0 | 33 |
| 45 | Carriers of a single CFTR mutation are asymptomatic: an evolving dogma?. European Respiratory Journal, 2020, 56, 2002645. | 3.1 | 5 |
| 46 | Lung immunoglobulin A immunity dysregulation in cystic fibrosis. EBioMedicine, 2020, 60, 102974. | 2.7 | 22 |
| 47 | Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. ERJ Open Research, 2020, 6, 00253-2020. | 1.1 | 10 |
| 48 | The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 868-871. | 0.3 | 74 |
| 49 | A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 355-358. | 0.3 | 113 |
| 50 | Airway mucus accumulation in COPD: the cholinergic paradox!. European Respiratory Journal, 2020, 55, 1902473. | 3.1 | 2 |
| 51 | â€œCanâ€™t Stop the Feelingâ€: Symptoms as the Key to Trial Success in Bronchiectasis?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1461-1462. | 2.5 | 2 |
| 52 | Validation of short- and long-term demographic forecasts using the Canadian Cystic Fibrosis Registry. European Respiratory Journal, 2020, 55, 1901667. | 3.1 | 2 |
| 53 | Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: A metaâ€anâ€alysis. Pediatric Pulmonology, 2020, 55, 2653-2661. | 1.0 | 12 |
| 54 | Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study. BMJ Open, 2020, 10, e035811. | 0.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Impact of COVID-19 on people with cystic fibrosis. Lancet Respiratory Medicine,the, 2020, 8, e35-e36. | 5.2 | 114 |
| 56 | Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 778-781. | 0.9 | 24 |
| 57 | Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores. Radiology: Cardiothoracic Imaging, 2020, 2, e200022. | 0.9 | 4 |
| 58 | Are there specific clinical characteristics associated with physicianâ€™s treatment choices in COPD?. Respiratory Research, 2019, 20, 189. | 1.4 | 5 |
| 59 | Predictors in routine practice of 6-min walking distance and oxygen desaturation in patients with COPD: impact of comorbidities . International Journal of COPD, 2019, Volume 14, 1399-1410. | 0.9 | 13 |
| 60 | Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulmonary Medicine, 2019, 19, 127. | 0.8 | 15 |
| 61 | Respiratory Medicine and Research: The new English-language journal of the SociÃ©tÃ© de pneumologie de langue franÃ§aise!. Respiratory Medicine and Research, 2019, 75, A1-A2. | 0.4 | 0 |
| 62 | Relationship between gender and survival in a real-life cohort of patients with COPD. Respiratory Research, 2019, 20, 191. | 1.4 | 14 |
| 63 | Do Cough and Sputum Production Predict COPD Exacerbations?. Chest, 2019, 156, 641-642. | 0.4 | 6 |
| 64 | Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death. European Respiratory Journal, 2019, 53, 1801943. | 3.1 | 11 |
| 65 | External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 8-17. | 0.7 | 7 |
| 66 | Artificial intelligence outperforms pulmonologists in the interpretation ofÂpulmonary function tests. European Respiratory Journal, 2019, 53, 1801660. | 3.1 | 102 |
| 67 | Validation of the French 3-year prognostic score using the Canadian Cystic Fibrosis registry. Journal of Cystic Fibrosis, 2019, 18, 396-398. | 0.3 | 11 |
| 68 | Acute and chronic non-pulmonary complications in adults with cystic fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 23-38. | 1.0 | 13 |
| 69 | Reply to Polverino: Deconvoluting Chronic Obstructive Pulmonary Disease: Are B Cells the Frontrunners?. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1171-1172. | 2.5 | 0 |
| 70 | Increased IgA Expression in Lung Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 592-602. | 2.5 | 40 |
| 71 | PP128 Quantifying The Relative Importance Of Chronic Obstructive Pulmonary Disease Symptoms To Patients. International Journal of Technology Assessment in Health Care, 2019, 35, 61-61. | 0.2 | 0 |
| 72 | Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 928-940. | 2.5 | 62 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | On Don Quixote and pink puffers: multi-organ loss of tissue COPD. European Respiratory Journal, 2018, 51, 1702560. | 3.1 | 2 |
| 74 | Blood eosinophil counts as a guide for COPD treatment strategies. Lancet Respiratory Medicine,the, 2018, 6, 78-80. | 5.2 | 4 |
| 75 | Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Medicine, 2018, 16, 33. | 2.3 | 21 |
| 76 | Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis. Journal of Clinical Pathology, 2018, 71, 752-753. | 1.0 | 4 |
| 77 | Automated computed tomographic scoring of lung disease in adults with primary ciliary dyskinesia. BMC Pulmonary Medicine, 2018, 18, 194. | 0.8 | 10 |
| 78 | Cured bronchi! Extending the use of nebulised hypertonic saline outside of cystic fibrosis?. European Respiratory Journal, 2018, 51, 1800755. | 3.1 | 0 |
| 79 | An attempt at modeling COPD epidemiological trends in France. Respiratory Research, 2018, 19, 130. | 1.4 | 13 |
| 80 | Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis. Mediators of Inflammation, 2018, 2018, 1-3. | 1.4 | 4 |
| 81 | A prospective analysis of unplanned patient-initiated contacts in an adult cystic fibrosis centre. Journal of Cystic Fibrosis, 2018, 17, 636-642. | 0.3 | 4 |
| 82 | Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected Lungs. Methods in Molecular Biology, 2018, 1845, 223-239. | 0.4 | 10 |
| 83 | An automated computed tomography score for the cystic fibrosis lung. European Radiology, 2018, 28, 5111-5120. | 2.3 | 16 |
| 84 | Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia. Thorax, 2017, 72, 154-160. | 2.7 | 77 |
| 85 | Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. European Respiratory Journal, 2017, 49, 1601873. | 3.1 | 38 |
| 86 | The changing epidemiology and demography of cystic fibrosis. Presse Medicale, 2017, 46, e87-e95. | 0.8 | 60 |
| 87 | Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. Journal of Cystic Fibrosis, 2017, 16, 388-391. | 0.3 | 81 |
| 88 | How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 139-149. | 2.5 | 68 |
| 89 | A simple algorithm for the identification of clinical COPD phenotypes. European Respiratory Journal, 2017, 50, 1701034. | 3.1 | 53 |
| 90 | A first step to STOP cystic fibrosis exacerbations. Journal of Cystic Fibrosis, 2017, 16, 529-531. | 0.3 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis. European Respiratory Journal, 2017, 50, 1700763. | 3.1 | 15 |
| 92 | Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2017, 17, 25. | 0.8 | 9 |
| 93 | Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Pediatric Pulmonology, 2017, 52, 190-197. | 1.0 | 33 |
| 94 | Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey. Journal of Cystic Fibrosis, 2017, 16, 85-88. | 0.3 | 21 |
| 95 | Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. International Journal of COPD, 2017, Volume 12, 1819-1824. | 0.9 | 81 |
| 96 | Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis. Frontiers in Cellular and Infection Microbiology, 2017, 7, 243. | 1.8 | 16 |
| 97 | <em>Aspergillus fumigatus</em> in the cystic fibrosis lung: pros and cons of azole therapy. Infection and Drug Resistance, 2016, Volume 9, 229-238. | 1.1 | 53 |
| 98 | Impact of current cough on health-related quality of life in patients with COPD. International Journal of COPD, 2016, Volume 11, 2091-2097. | 0.9 | 43 |
| 99 | Exacerbations of COPD. International Journal of COPD, 2016, 11 Spec Iss, 21. | 0.9 | 79 |
| 100 | Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor. European Respiratory Journal, 2016, 48, 249-252. | 3.1 | 30 |
| 101 | Renin-associated hypertension after bronchial artery embolization in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 213-215. | 0.3 | 4 |
| 102 | CFTR and/or pancreatitis susceptibility genes mutations as risk factors of pancreatitis in cystic fibrosis patients?. Pancreatology, 2016, 16, 515-522. | 0.5 | 6 |
| 103 | Toward Personalized Prescription of Systemic Steroids for Patients Hospitalized With COPD Exacerbations. Chest, 2016, 150, 268-269. | 0.4 | 2 |
| 104 | DCTN4 as a modifier of chronicPseudomonas aeruginosainfection in cystic fibrosis. Clinical Respiratory Journal, 2016, 10, 777-783. | 0.6 | 10 |
| 105 | Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!. Journal of Cystic Fibrosis, 2016, 15, 204-212. | 0.3 | 76 |
| 106 | Neutrophil-Expressed p21/waf1 Favors Inflammation Resolution in<i>Pseudomonas aeruginosa</i>Infection. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 740-750. | 1.4 | 20 |
| 107 | Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. European Respiratory Journal, 2016, 47, 420-428. | 3.1 | 102 |
| 108 | Modeling future COPD epidemiology. , 2016, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Complications of Peripherally Inserted Central Catheters in Adults with Cystic Fibrosis or Bronchiectasis. Journal of Vascular Access, 2015, 16, 245-249. | 0.5 | 13 |
| 110 | Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 1663. | 0.9 | 70 |
| 111 | Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. Journal of Cystic Fibrosis, 2015, 14, 594-599. | 0.3 | 37 |
| 112 | Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment. European Respiratory Journal, 2015, 45, 260-262. | 3.1 | 4 |
| 113 | United Airway Diseases. Should We Add Upper Airway Inflammatory Disorders to the List of Chronic Obstructive Pulmonary Disease Comorbidities?. Annals of the American Thoracic Society, 2015, 12, 968-970. | 1.5 | 5 |
| 114 | Future trends in cystic fibrosis demography in 34 European countries. European Respiratory Journal, 2015, 46, 133-141. | 3.1 | 238 |
| 115 | An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27. | 2.5 | 166 |
| 116 | An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905. | 3.1 | 138 |
| 117 | Hostâ€“microbe interactions in distal airways: relevance to chronic airway diseases. European Respiratory Review, 2015, 24, 78-91. | 3.0 | 35 |
| 118 | Identification of Clinical Phenotypes Using Cluster Analyses in COPD Patients with Multiple Comorbidities. BioMed Research International, 2014, 2014, 1-9. | 0.9 | 55 |
| 119 | Association of chronic nasal symptoms with dyspnoea and qualityâ€ofâ€life impairment in chronic obstructive pulmonary disease. Respirology, 2014, 19, 346-352. | 1.3 | 15 |
| 120 | Monitoring disease progression in COPD patients: one step beyond!. European Respiratory Journal, 2014, 43, 665-667. | 3.1 | 0 |
| 121 | Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?. European Respiratory Journal, 2014, 43, 1201-1203. | 3.1 | 31 |
| 122 | Impact of gender on COPD expression in a real-life cohort. Respiratory Research, 2014, 15, 20. | 1.4 | 35 |
| 123 | Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity. Nature Communications, 2014, 5, 5105. | 5.8 | 110 |
| 124 | Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respiratory Research, 2014, 15, 64. | 1.4 | 11 |
| 125 | p.Arg75Gln, a CFTR variant involved in the risk of CFTR-related disorders?. Journal of Human Genetics, 2014, 59, 206-210. | 1.1 | 11 |
| 126 | Targeting Mucus Hypersecretion: New Therapeutic Opportunities for COPD?. Drugs, 2014, 74, 1073-1089. | 4.9 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Multimorbidity in Elderly Patients with Chronic Obstructive Pulmonary Disease: Stop Smoking! Go Exercise?. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 7-8. | 2.5 | 4 |
| 128 | Prognostic value of six minute walk test in cystic fibrosis adults. Respiratory Medicine, 2013, 107, 1881-1887. | 1.3 | 51 |
| 129 | Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 497-503. | 0.3 | 103 |
| 130 | Impact of comorbidities on COPD-specific health-related quality of life. Respiratory Medicine, 2013, 107, 233-241. | 1.3 | 103 |
| 131 | Chronic Cough in Chronic Obstructive Pulmonary Disease: Time for Listening?. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 902-904. | 2.5 | 9 |
| 132 | CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium. European Respiratory Journal, 2013, 42, 1553-1562. | 3.1 | 19 |
| 133 | Dysfunctional lung anatomy and small airways degeneration in COPD. International Journal of COPD, 2013, 8, 7. | 0.9 | 17 |
| 134 | Chronic cough and sputum production: a clinical COPD phenotype?: Table 1â€“. European Respiratory Journal, 2012, 40, 4-6. | 3.1 | 33 |
| 135 | Pulmonary Acceleration Time to Optimize the Timing of Lung Transplant in Cystic Fibrosis. Pulmonary Circulation, 2012, 2, 75-83. | 0.8 | 13 |
| 136 | Targeting cytosolic proliferating cell nuclear antigen in neutrophil-dominated inflammation. Frontiers in Immunology, 2012, 3, 311. | 2.2 | 31 |
| 137 | Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 936-937. | 2.5 | 4 |
| 138 | Bronchial rupture related to endobronchial stenting in relapsing polychondritis. European Respiratory Review, 2012, 21, 367-369. | 3.0 | 14 |
| 139 | Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis. Archives of Disease in Childhood, 2012, 97, 960-966. | 1.0 | 47 |
| 140 | Clinical COPD phenotypes identified by cluster analysis: validation with mortality. European Respiratory Journal, 2012, 40, 495-496. | 3.1 | 38 |
| 141 | High Prevalence of Azole-Resistant Aspergillus fumigatus in Adults with Cystic Fibrosis Exposed to Itraconazole. Antimicrobial Agents and Chemotherapy, 2012, 56, 869-874. | 1.4 | 164 |
| 142 | Employment and work disability in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 137-143. | 0.3 | 30 |
| 143 | Association between occupational exposure and the clinical characteristics of COPD. BMC Public Health, 2012, 12, 302. | 1.2 | 22 |
| 144 | Everolimus-related organizing pneumonia: a report establishing causality. Investigational New Drugs, 2012, 30, 1244-1247. | 1.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Two Distinct Chronic Obstructive Pulmonary Disease (COPD) Phenotypes Are Associated with High Risk of Mortality. PLoS ONE, 2012, 7, e51048. | 1.1 | 104 |
| 146 | Liver disease in adult patients with cystic fibrosis: A frequent and independent prognostic factor associated with death or lung transplantation. Journal of Hepatology, 2011, 55, 1377-1382. | 1.8 | 64 |
| 147 | Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. Journal of Experimental Medicine, 2011, 208, 1635-1648. | 4.2 | 739 |
| 148 | Mediastinal Tuberculosis in an Adult Patient with Cystic Fibrosis. Journal of Clinical Microbiology, 2011, 49, 750-751. | 1.8 | 8 |
| 149 | Cystic Fibrosis Transmembrane Conductance Regulator Channel Dysfunction in Nonâ€“Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1078-1084. | 2.5 | 85 |
| 150 | Î²2-Agonist modulates epithelial gene expression involved in the T- and B-cell chemotaxis and induces airway sensitization in human isolated bronchi. Pharmacological Research, 2010, 61, 121-128. | 3.1 | 12 |
| 151 | Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Medical Mycology, 2010, 48, S32-S36. | 0.3 | 114 |
| 152 | Cough and Sputum Production Are Associated With Frequent Exacerbations and Hospitalizations in COPD Subjects. Chest, 2009, 135, 975-982. | 0.4 | 299 |
| 153 | Heme Oxygenase-1 Prevents Airway Mucus Hypersecretion Induced by Cigarette Smoke in Rodents and Humans. American Journal of Pathology, 2008, 173, 981-992. | 1.9 | 40 |
| 154 | Practice of noninvasive ventilation for cystic fibrosis: a nationwide survey in France. Respiratory Care, 2008, 53, 1482-9. | 0.8 | 27 |
| 155 | A morphometric study of mucins and small airway plugging in cystic fibrosis. Thorax, 2007, 62, 153-161. | 2.7 | 125 |
| 156 | MUC5AC, a Gel-Forming Mucin Accumulating in Gallstone Disease, Is Overproduced via an Epidermal Growth Factor Receptor Pathway in the Human Gallbladder. American Journal of Pathology, 2006, 169, 2031-2041. | 1.9 | 47 |
| 157 | Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study. Respiratory Research, 2006, 7, 14. | 1.4 | 43 |
| 158 | One-year Outcome after Severe Pulmonary Exacerbation in Adults with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 158-164. | 2.5 | 112 |
| 159 | IL-13-induced Clara cell secretory protein expression in airway epithelium: role of EGFR signaling pathway. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L67-L75. | 1.3 | 40 |
| 160 | Mucus and Mucin-Secreting Cells. , 2002, , 155-163. | | 2 |
| 161 | The role of epidermal growth factor in mucus production. Current Opinion in Pharmacology, 2001, 1, 254-258. | 1.7 | 74 |
| 162 | Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L165-L172. | 1.3 | 230 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L134-L140. | 1.3 | 217 |
| 164 | Human Eosinophils Induce Mucin Production in Airway Epithelial Cells Via Epidermal Growth Factor Receptor Activation. Journal of Immunology, 2001, 167, 5948-5954. | 0.4 | 132 |
| 165 | Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. Journal of Allergy and Clinical Immunology, 2000, 105, 739-745. | 1.5 | 40 |
| 166 | Relation of epidermal growth factor receptor expression to goblet cell hyperplasia in nasal polyps. Journal of Allergy and Clinical Immunology, 2000, 106, 705-712. | 1.5 | 69 |